Short answer
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Earnings release covers Q4 and full-year periods ended December 31, 2025; reconciliation tables included in press release exhibit.
INTEGRA LIFESCIENCES HOLDINGS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Earnings release covers Q4 and full-year periods ended December 31, 2025; reconciliation tables included in press release exhibit
- Goodwill impairment charges excluded from adjusted results: triggered by tariff uncertainty, quality/operational issues, and market cap decline, signaling material business stress
- Boston facility recall charges (products distributed March 2018–May 2023) and Braintree transition costs continue to be excluded from adjusted metrics
- Forward-looking guidance provided only on organic revenue and adjusted EPS basis: no GAAP reconciliation provided due to high variability in FX, M&A, and restructuring items
- Multiple recurring "non-recurring" exclusions (structural optimization, EU MDR, acquisition costs) warrant scrutiny of how much adjusted EPS diverges from GAAP EPS
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other INTEGRA LIFESCIENCES HOLDINGS CORP 8-K filings
Get the next IART 8-K as it lands
Follow IART for push alerts, or ask the research agent what this filing means.